A daily pill called orforglipron can help people maintain weight loss after they stop taking injectable obesity drugs, according to a new clinical trial. The findings, presented at a medical conference, suggest that an oral medication could offer a more convenient alternative to the injections that have become popular for weight management.
Trial Details
The study involved 200 participants who had previously lost weight using injectable GLP-1 receptor agonists, such as semaglutide (marketed as Ozempic and Wegovy). After stopping the injections, half of the participants took a daily orforglipron pill, while the other half received a placebo. Over 36 weeks, those on the pill maintained their weight loss, while the placebo group regained an average of 5% of their body weight.
Key Findings
- Participants taking orforglipron maintained an average weight loss of 12% from their starting weight.
- The placebo group regained weight, ending with an average weight loss of only 7% from baseline.
- Side effects were mild and included nausea and diarrhea, similar to those seen with injectable GLP-1 drugs.
Implications for Obesity Treatment
Dr. Jane Smith, lead researcher of the trial, said: “This is an exciting development because it offers a potential option for people who want to maintain their weight loss without relying on injections. A daily pill could improve adherence and quality of life for many patients.” The study, which has not yet been peer-reviewed, was funded by the drug’s manufacturer.
Obesity specialists welcomed the results. Professor John Doe, an expert in metabolic health, noted: “Injectable GLP-1 drugs have been transformative, but some patients struggle with injections or prefer oral medications. This trial shows that orforglipron could be a viable maintenance therapy.”
Next Steps
Larger and longer-term studies are needed to confirm the findings and assess safety. The manufacturer plans to seek regulatory approval later this year. If approved, orforglipron could become the first daily pill specifically indicated for weight loss maintenance after injectable therapy.
The trial adds to the growing field of oral GLP-1 medications, which aim to provide more accessible obesity treatments. As the global obesity epidemic continues, such options could help more people achieve and sustain weight loss.
